THV 01

Drug Profile

THV 01

Alternative Names: THV01; THV01-1; THV01-2

Latest Information Update: 01 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator THERAVECTYS
  • Class AIDS vaccines; Dendritic cell vaccines; Gene therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II HIV infections

Most Recent Events

  • 01 Dec 2017 THV 01 is still in phase I/II trials for HIV infections (Theravectys website, December 2017)
  • 23 Mar 2015 THERAVECTYS completes phase I/II trials in HIV infections in Belgium and France (NCT02054286)
  • 03 Dec 2014 THERAVECTYS has patent protection for lentiviral vector technology in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top